利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.018 秒)

    EFFERVESCENT FORMULATIONS COMPRISING DESMOPRESSIN
    3.
    发明申请
    EFFERVESCENT FORMULATIONS COMPRISING DESMOPRESSIN 审中-公开
    包含降粘剂的有效配方

    公开(公告)号：WO2005089724A1

    公开(公告)日：2005-09-29

    申请号：PCT/GB2005/001136

    申请日：2005-03-18

    申请人： ARDANA BIOSCIENCE LIMITED ,  LARSEN, Finn

    发明人： LARSEN, Finn

    IPC分类号： A61K9/46

    CPC分类号： A61K9/0007 ,  A61K9/5073 ,  A61K38/11

    摘要： An effervescent formulation comprising desmopressin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising desmopressin wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the desmopressin. The formulation is used for treating diabetes insipidus, nocturnal enuresis, postoperative polyuria or polydipsia, nocturia associated with multiple sclerosis, mild to moderate haemophilia or von Willebrand’s disease.

    摘要翻译： 包含去氨加压素的泡腾制剂，优选包含含有酸性物质，碱性物质和水溶性隔离剂的多层泡腾微球。 包含去氨加压素的泡腾制剂，其中在多层泡腾微球中的溶解在几乎立即起泡后导致去氨加压素的溶液或均匀分散体。 该制剂用于治疗尿崩症，夜间遗尿，术后多尿或烦渴，与多发性硬化相关的夜尿症，轻度至中度血友病或血管性血友病。

    EFFERVESCENT FORMULATIONS COMPRISING APOMORPHINE
    5.
    发明申请
    EFFERVESCENT FORMULATIONS COMPRISING APOMORPHINE 审中-公开
    包含APOMORPHINE的有效配方

    公开(公告)号：WO2004026309A1

    公开(公告)日：2004-04-01

    申请号：PCT/GB2003/004141

    申请日：2003-09-19

    申请人： ARDANA BIOSCIENCE LIMITED ,  LARSEN, Finn

    发明人： LARSEN, Finn

    IPC分类号： A61K31/485

    CPC分类号： A61K31/485 ,  A61K9/0007 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018

    摘要： An effervescent formulation comprising apomorphine, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising apomorphine wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the apomorphine. The formulation is used for the treatment of male and female sexual dysfunction.

    摘要翻译： 包含阿扑吗啡的泡腾制剂，优选包含含有酸性物质，碱性物质和水溶性隔离剂的多层泡腾微球。 包含阿扑吗啡的泡腾制剂，其中多层泡腾微球的溶解在几乎立即起泡之后导致阿朴吗啡的溶液或均匀分散体。 该制剂用于治疗男性和女性性功能障碍。

    DAYSPEPSIA TREATMENT WITH ALGINATE
    7.
    发明申请
    DAYSPEPSIA TREATMENT WITH ALGINATE 审中-公开
    用氨基酸治疗的DAYSPEPSIA治疗

    公开(公告)号：WO2010108494A1

    公开(公告)日：2010-09-30

    申请号：PCT/DK2010/000036

    申请日：2010-03-25

    申请人： S-BIOTEK HOLDING ApS ,  OLSEN, Jens, Steen ,  LARSEN, Finn

    发明人： OLSEN, Jens, Steen ,  LARSEN, Finn

    IPC分类号： A61K47/36 ,  A61P1/14

    CPC分类号： A61K47/36 ,  A61K9/0053

    摘要： The present invention relates to a pharmaceutical composition comprising alginate. The pharmaceutical composition is intended for the treatment of dyspepsia in a mammal, wherein the composition comprises an alkali metal alginate, the average molecular weight being 150,000 or below, for reaction with excess stomach acid thereby forming a protonated alginic acid and a salt comprising cross-linking polyvalent metal ions in an amount based on the weight of the alginate of less than 1 % by weight.

    摘要翻译： 本发明涉及包含藻酸盐的药物组合物。 药物组合物旨在用于治疗哺乳动物的消化不良，其中组合物包含碱金属藻酸盐，平均分子量为15万或更低，用于与过量的胃酸反应，从而形成质子化海藻酸和包含交联的盐， 以基于藻酸盐的重量计小于1重量％的量连接多价金属离子。

    INSERT FOR WATER OUTLET
    8.
    发明申请
    INSERT FOR WATER OUTLET 审中-公开
    插入水箱

    公开(公告)号：WO2010085152A1

    公开(公告)日：2010-07-29

    申请号：PCT/NO2009/000028

    申请日：2009-01-23

    申请人： FRANKFURT MALTA HOLDING LTD. ,  LARSEN, Finn, Thorvald

    发明人： LARSEN, Finn, Thorvald

    IPC分类号： B05B1/30 ,  G05D7/01

    CPC分类号： B05B1/265 ,  B05B1/18 ,  E03C1/08 ,  E03C2001/026 ,  Y02A20/414

    摘要： Insert to be used with different types of water outlets, such as shower heads, water taps, hoses for watering and so on. The insert has a mouthpiece (1) with a central axial channel (8) for through flow, and a rotationally symmetrical deflector element (6) for the water is situated in the vicinity of the outer mouth of the channel. The deflector element (6) is held in place by a stem (3) with radial clearance to the channel, and surrounded by a conical surface (7). The mouthpiece (1) delimits a cavity (9) around and axially outside the deflector element (6), and the conical surface (7) converges axially outwards. The end of the stem (3) opposite of the deflector element (6) is connected to a head (10), which head has at least one bore which supplies water to the channel (8). A regulator (1 1, 21, 23) to achieve a substantially constant flow of water independent of the supply water pressure, is integrated in the head (10). The regulator comprises substantially axial grooves (1 1 ) on the outside end of the head (10) and an O-ring (21) which is placed around the grooves (11 ) and is influenced by the water pressure, and successively is being pressed into the grooves with increasing water pressure.

    摘要翻译： 插入用于不同类型的出水口，如淋浴头，水龙头，浇水软管等。 插入件具有一个具有用于通过流动的中心轴向通道（8）的接口（1），并且用于水的旋转对称的偏转元件（6）位于通道的外口附近。 偏转元件（6）通过具有径向间隙的杆（3）保持在适当的位置，并且被圆锥形表面（7）包围。 接口（1）限定了偏转元件（6）周围和轴向外侧的空腔（9），并且锥形表面（7）向外轴向会聚。 与偏转元件（6）相对的杆（3）的端部连接到头部（10），头部具有至少一个向通道（8）供水的孔。 在头部（10）中集成有用于实现与供水压力无关的基本恒定的水流量的调节器（11,21,23）。 调节器包括在头部（10）的外端上的基本上是轴向的凹槽（11）和围绕凹槽（11）放置并且受到水压的影响的O形环（21），并且连续地被按压 随着水压增加进入槽。

    ADMINISTRATION OF THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST TEVERELIX
    9.
    发明申请
    ADMINISTRATION OF THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST TEVERELIX 审中-公开
    腺苷二磷酸腺苷拮抗剂TEVERELIX的施用

    公开(公告)号：WO2008071984A1

    公开(公告)日：2008-06-19

    申请号：PCT/GB2007/004798

    申请日：2007-12-13

    申请人： ARDANA BIOSCIENCE LIMITED ,  LARSEN, Finn ,  MACLEAN, Carol

    发明人： LARSEN, Finn ,  MACLEAN, Carol

    IPC分类号： A61P15/16 ,  A61P35/00 ,  A61K38/09

    CPC分类号： A61K38/09

    摘要： The invention provides methods of achieving, and/or maintaining for prolonged periods, chemical castration in a primate in need of such chemical castration. Said methods include those aimed at achieving chemical castration and comprising administration of sufficient teverelix, or pharmaceutically acceptable salt thereof, to provide a concentration of teverelix in the blood plasma of a primate of at least 9 ng/ mL. The invention also provides kits-of-parts for use in such methods.

    摘要翻译： 本发明提供了在需要这种化学去势的灵长类动物中实现和/或维持长时间化学去势的方法。 所述方法包括那些旨在实现化学去势的方法，并且包括施用足够的特夫瑞瑞克或其药学上可接受的盐以在灵长类动物血浆中提供至少9ng / mL的浓度。 本发明还提供了用于这些方法的零件套件。

    METHODS AND KITS TO DIAGNOSE GROWTH HORMONE DEFICIENCY
    10.
    发明申请
    METHODS AND KITS TO DIAGNOSE GROWTH HORMONE DEFICIENCY 审中-公开
    诊断生长激素缺陷的方法和工具

    公开(公告)号：WO2007093820A1

    公开(公告)日：2007-08-23

    申请号：PCT/GB2007/000566

    申请日：2007-02-19

    申请人： ARDANA BIOSCIENCE LIMITED ,  LARSEN, Finn

    发明人： LARSEN, Finn

    IPC分类号： G01N33/74

    CPC分类号： G01N33/74

    摘要： A method of assessing growth hormone deficiency in a human or animal subject, the method comprising administering orally to the subject EP 1572 (Formula I) or EP 1573 (Formula II), obtaining a post-administration sample from the subject, determining the level of growth hormone in the sample and assessing whether the level of growth hormone in the sample is indicative of growth hormone deficiency in the subject. Preferably, the GH level in the sample is measured by immunoassay. Also disclosed is a kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample.

    摘要翻译： 一种评估人或动物受试者生长激素缺乏症的方法，所述方法包括口服施用受试者EP 1572（式I）或EP 1573（式II），获得受试者的给药后样品， 样本中的生长激素，并评估样品中生长激素的水平是否表明受试者的生长激素缺乏。 优选地，通过免疫测定来测量样品中的GH水平。 还公开了构成诊断试剂盒的试剂盒，其包括：（a）配制​​用于口服给药的EP 1572或EP 1573; 和（b）用于确定样品中生长激素水平的方法。